Leukemia drug Asciminib's Long-Term safety tracked in ongoing study

NCT ID NCT04877522

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study follows people with chronic myeloid leukemia (CML) who have already benefited from the drug asciminib in earlier Novartis trials. Researchers want to see how safe the drug is over the long term. About 347 participants will continue taking asciminib or other similar drugs and be monitored for side effects. No new treatment is being tested—this is about checking safety for those already on the medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Asciminib (also known as ABL001), imatinib, nilotinib, bosutinib, dasatinib
What this could lead to: If successful, this study will confirm that long-term use of asciminib is safe for controlling chronic myeloid leukemia.
What could go wrong: This is an observational roll-over study, not a test of a new treatment. It only includes patients already benefiting, so results may not apply to everyone. Side effects are still possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic myelogenous leukemia, BCR-ABL1 positive leukemia, acute lymphocytic, susceptibility to, 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Myeloproliferative Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOGENOUS LEUKEMIA LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE

Contacts and locations

Locations

Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering
RECRUITING

New York, New York, 10017, United States
Michigan Med University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109 5271, United States
Novartis Investigative Site
RECRUITING

CABA, Buenos Aires, C1221ADC, Argentina
Novartis Investigative Site
RECRUITING

Capital Federal, C1114AAN, Argentina
Novartis Investigative Site
RECRUITING

Graz, 8036, Austria
Novartis Investigative Site
RECRUITING

Vienna, 1140, Austria
Novartis Investigative Site
COMPLETED

Rio de Janeiro, Rio de Janeiro, 20211-030, Brazil
Novartis Investigative Site
COMPLETED

São Paulo, São Paulo, 05403 000, Brazil
Novartis Investigative Site
COMPLETED

São Paulo, São Paulo, 08270-070, Brazil
Novartis Investigative Site
RECRUITING

Varna, 9000, Bulgaria
Novartis Investigative Site
RECRUITING

Montreal, Quebec, H1T 2M4, Canada
Novartis Investigative Site
RECRUITING

Chongqing, Chongqing Municipality, 400010, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site
RECRUITING

Zhengzhou, Henan, 450008, China
Novartis Investigative Site
RECRUITING

Wuhan, Hubei, 430022, China
Novartis Investigative Site
RECRUITING

Changchun, Jilin, 130021, China
Novartis Investigative Site
RECRUITING

Xian, Shanxi, 710004, China
Novartis Investigative Site
COMPLETED

Chengdu, Sichuan, 610041, China
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Beijing, 100044, China
Novartis Investigative Site
RECRUITING

Beijing, 100730, China
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Shanghai, 200025, China
Novartis Investigative Site
RECRUITING

Shenyang, 110004, China
Novartis Investigative Site
RECRUITING

Tianjin, 300020, China
Novartis Investigative Site
RECRUITING

Ostrava, Poruba, 708 52, Czechia
Novartis Investigative Site
RECRUITING

Brno, 625 00, Czechia
Novartis Investigative Site
COMPLETED

Copenhagen, DK-2100, Denmark
Novartis Investigative Site
RECRUITING

Bordeaux, 33076, France
Novartis Investigative Site
RECRUITING

Lyon, 69373, France
Novartis Investigative Site
RECRUITING

Marseille, 13273, France
Novartis Investigative Site
RECRUITING

Nantes, 44093, France
Novartis Investigative Site
RECRUITING

Paris, 75475, France
Novartis Investigative Site
RECRUITING

Vandœuvre-lès-Nancy, 54511, France
Novartis Investigative Site
RECRUITING

Frankfurt am Main, Hesse, 60590, Germany
Novartis Investigative Site
RECRUITING

Jena, Thuringia, 07740, Germany
Novartis Investigative Site
RECRUITING

Berlin, 13353, Germany
Novartis Investigative Site
RECRUITING

Kiel, 24116, Germany
Novartis Investigative Site
RECRUITING

Milan, MI, 20162, Italy
Novartis Investigative Site
RECRUITING

Roma, RM, 00161, Italy
Novartis Investigative Site
COMPLETED

Naples, 80131, Italy
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Kobe, Hyōgo, 650-0017, Japan
Novartis Investigative Site
COMPLETED

Beirut, 113-0236, Lebanon
Novartis Investigative Site
RECRUITING

George Town, Pulau Pinang, 10450, Malaysia
Novartis Investigative Site
RECRUITING

Johor Bahru, 80100, Malaysia
Novartis Investigative Site
RECRUITING

Kuala Selangor, 68000, Malaysia
Novartis Investigative Site
RECRUITING

Monterrey, Nuevo León, 64460, Mexico
Novartis Investigative Site
RECRUITING

Khoudh, 123, Oman
Novartis Investigative Site
RECRUITING

Katowice, 40-519, Poland
Novartis Investigative Site
COMPLETED

Krakow, 30-688, Poland
Novartis Investigative Site
RECRUITING

Warsaw, 00-791, Poland
Novartis Investigative Site
COMPLETED

Wroclaw, 50 367, Poland
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Lisbon, 1099-023, Portugal
Novartis Investigative Site
RECRUITING

Porto, 4200-072, Portugal
Novartis Investigative Site
COMPLETED

Timișoara, 300079, Romania
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Moscow, 125167, Russia
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Moscow, 125284, Russia
Novartis Investigative Site
RECRUITING

Saint Petersburg, 191024, Russia
Novartis Investigative Site
RECRUITING

Saint Petersburg, 197341, Russia
Novartis Investigative Site
COMPLETED

Riyadh, 11211, Saudi Arabia
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Singapore, 169608, Singapore
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Uijeongbu-si, Gyeonggi-do, 11759, South Korea
Novartis Investigative Site
COMPLETED

Busan, 49201, South Korea
Novartis Investigative Site
COMPLETED

Jeollanam, 519763, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 03080, South Korea
Novartis Investigative Site
RECRUITING

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site
RECRUITING

Badalona, Barcelona, 08916, Spain
Novartis Investigative Site
COMPLETED

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site
RECRUITING

Bilbao, Bizkaia, 48013, Spain
Novartis Investigative Site
RECRUITING

Santa Cruz, Santa Cruz De Tenerife, 38009, Spain
Novartis Investigative Site
RECRUITING

Barcelona, 08035, Spain
Novartis Investigative Site
COMPLETED

Barcelona, 08036, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28006, Spain
Novartis Investigative Site
COMPLETED

Madrid, 28034, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28041, Spain
Novartis Investigative Site
RECRUITING

Seville, 41009, Spain
Novartis Investigative Site
RECRUITING

Valencia, 46026, Spain
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Taoyuan, 33305, Taiwan
Novartis Investigative Site
RECRUITING

Samsun, Atakum, 55200, Turkey (Türkiye)
Novartis Investigative Site
RECRUITING

London, W12 0HS, United Kingdom
Novartis Investigative Site
RECRUITING

Oxford, OX3 7LE, United Kingdom
Novartis Investigative Site
RECRUITING

Hanoi, 100000, Vietnam
Novartis Investigative Site
RECRUITING

Ho Chi Minh City, 70000, Vietnam
Oregon Health Sciences University
ACTIVE_NOT_RECRUITING

Portland, Oregon, 97239, United States
Texas Oncology
RECRUITING

Dallas, Texas, 75251, United States
Uni Of TX MD Anderson Cancer Cntr
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.